Jiangsu Vcare Pharmaceutical Technology Co., Ltd

This early-stage study looks at how a single 25 mg dose of VC005 tablets behaves in the body of people with kidney impairment compared to those with normal kidneys. The goal is to understand safety and drug levels, not to treat the kidney disease. 32 adults will take part.

This early-stage study looks at how taking VC005 tablets with or without food changes the drug's levels in the blood. It involves 30 healthy adults aged 18 to 45. The results will help guide future dosing for atopic dermatitis (eczema) patients.

This early-stage study looks at how a single 25 mg dose of VC005 tablets is handled by the body in people with mild or moderate liver impairment compared to those with normal liver function. The goal is to measure drug levels and safety, not to treat the liver condition. 24 adult…